Verition Fund Management
TGTX icon

Verition Fund Management’s TG Therapeutics TGTX Stock Holding History

Verition Fund Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
+36,013
New +$1.47M 0.01% 1117
2025
Q4 		– Sell
-46,896
Closed -$1.69M – 3943
2025
Q3 		$1.69M Buy
46,896
+19,265
+70% +$635K 0.01% 2113
2025
Q2 		$994K Sell
27,631
-2,514
-8% -$93.6K ﹤0.01% 2480
2025
Q1 		$1.19M Buy
30,145
+10,680
+55% +$359K 0.01% 1990
2024
Q4 		$586K Sell
19,465
-26,234
-57% -$753K ﹤0.01% 2383
2024
Q3 		$1.07M Sell
45,699
-6,613
-13% -$144K 0.01% 1842
2024
Q2 		$931K Buy
52,312
+35,655
+214% +$569K 0.01% 1718
2024
Q1 		$253K Buy
16,657
+2,553
+18% +$40.7K ﹤0.01% 2385
2023
Q4 		$241K Sell
14,104
-39,003
-73% -$453K ﹤0.01% 1915
2023
Q3 		$444K Buy
53,107
+38,292
+258% +$534K 0.01% 1511
2023
Q2 		$368K Sell
14,815
-10,180
-41% -$263K ﹤0.01% 1407
2023
Q1 		$376K Buy
+24,995
New +$380K 0.01% 1391

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Verition Fund Management's TGTX Position: Q2 2026 in Review

Verition Fund Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 36,013 shares worth $1.98M. The stake represents 0.01% of the portfolio and ranks #1117 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in TGTX as recently as Q3 2025.

Verition Fund Management first reported a position in TGTX in Q1 2023 and has held it in 12 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Verition Fund Management held 36,013 shares of TG Therapeutics worth $1.98M as of Q2 2026.
  • TG Therapeutics was a new Verition Fund Management position in Q2 2026.
  • TG Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1117 holding.
  • Verition Fund Management first reported a position in TG Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.